Kezar Life Sciences(KZR)
Search documents
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
Prnewswire· 2026-03-30 17:35
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) Accessibility StatementSkip Navigation NEW YORK, March 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverdewith Monteverde & Associates PC(the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City ...
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
Prnewswire· 2026-03-30 16:25
<!doctype html> <!-- For structured data --> <!-- For language declaration --> Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationMILWAUKEE, March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Aurinia.Click hereto le ...
Kezar Life Sciences(KZR) - 2025 Q4 - Annual Report
2026-03-27 20:15
Washington, D.C. 20549 ________________________________________________________ FORM 10-K ________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38542 ________________________________________________________ ...
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
Businesswire· 2026-01-09 11:01
Core Viewpoint - Kezar Life Sciences has received a Type C meeting from the FDA to discuss the development of zetomipzomib for autoimmune hepatitis, indicating progress in its clinical development and potential for addressing unmet medical needs in this area [1][2][3] Group 1: Company Overview - Kezar Life Sciences is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases [4] - Zetomipzomib is a selective immunoproteasome inhibitor being evaluated for autoimmune hepatitis and has potential applications in multiple chronic immune-mediated diseases [5] Group 2: Clinical Development - The Type C meeting will review a proposed global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory autoimmune hepatitis [2] - Kezar submitted pharmacokinetic and hepatic safety data from previous trials to support its proposal for parallel studies in autoimmune hepatitis and hepatic impairment [2] Group 3: Market Need - Autoimmune hepatitis is a rare chronic disease affecting approximately 100,000 individuals in the U.S., with a significant unmet medical need for effective treatments [6] - Current standard treatments involve chronic immunosuppressive therapies that can lead to severe side effects, highlighting the need for alternatives that minimize or eliminate the use of corticosteroids [6] Group 4: Strategic Initiatives - The company is undergoing a strategic review process to maximize shareholder value, which includes workforce reductions and cost-containment measures [3] - Kezar has engaged TD Cowen to assist in this strategic review, indicating a focus on enhancing shareholder returns [3]
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
ZACKS· 2026-01-05 18:00
Core Viewpoint - Kezar Life Sciences, Inc. (KZR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by an upward trend in earnings estimates, which significantly influences stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining stock price movements, making it a valuable tool for investors [2][4]. - The correlation between earnings estimate revisions and stock price movements is strong, largely due to institutional investors who adjust their valuations based on these estimates [4]. Company Performance and Investor Sentiment - The upgrade reflects an improvement in Kezar Life Sciences' underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for Kezar Life Sciences has increased by 57.1%, indicating a significant upward revision in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimates into five groups, with a proven track record of performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Kezar Life Sciences' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 (NASDAQ:KZR)
Seeking Alpha· 2025-11-13 05:53
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
Kezar Life Sciences(KZR) - 2025 Q3 - Quarterly Report
2025-11-12 21:21
Financial Performance - The company reported a net loss of $41.5 million for the nine months ended September 30, 2025, compared to a net loss of $63.5 million for the same period in 2024, reflecting a decrease of $22.0 million [134]. - Total operating expenses for the nine months ended September 30, 2025, were $43.9 million, down from $69.0 million in 2024, representing a decrease of $25.1 million [134]. - The net loss for the nine months ended September 30, 2025, was $41.5 million, with an accumulated deficit of $476.0 million as of the same date [142]. - Cash used in operating activities was $39.8 million for the nine months ended September 30, 2025, compared to $57.4 million for the same period in 2024 [154]. - The company anticipates additional losses in the future as it evaluates strategic alternatives and manages discretionary spending [145]. Research and Development - Research and development expenses decreased by $21.0 million for the nine months ended September 30, 2025, primarily due to a reduction in clinical expenses from the termination of the PALIZADE trial and completion of the PORTOLA trial [135]. - Research and development expenses for the three months ended September 30, 2025, were $6.9 million, down from $16.2 million in 2024, a decrease of $9.3 million [129]. - The FDA removed the partial clinical hold on the PORTOLA Phase 2a clinical trial for zetomipzomib in July 2025, but a proposed registrational trial for relapsed and refractory autoimmune hepatitis was not aligned with the FDA [113][114]. Expenses and Charges - General and administrative expenses for the three months ended September 30, 2025, decreased by $0.9 million to $4.8 million compared to $5.7 million in 2024 [131]. - Restructuring and impairment charges decreased by $1.5 million for the nine months ended September 30, 2025, compared to the same period in 2024 [137]. - Interest income decreased by $1.0 million for the three months ended September 30, 2025, primarily due to a decrease in cash equivalents and lower interest rates [132]. - Interest income decreased by $3.1 million for the nine months ended September 30, 2025, primarily due to lower cash equivalents and interest rates [139]. Strategic Initiatives - The company is exploring strategic alternatives, including a restructuring plan and workforce reduction, to maximize stockholder value [115]. - The company reduced its workforce by approximately 70% as part of cost reduction efforts, estimating cash expenditures of about $6.0 million [144]. - The company has no committed external sources of funding and may need to pursue financing through equity offerings, debt financings, and collaborations [152]. Cash and Investments - As of September 30, 2025, the company had $90.2 million in cash, cash equivalents, and marketable securities, with an average maturity of approximately two months [141]. - Net cash provided by investing activities was $40.9 million for the nine months ended September 30, 2025, primarily from maturities of marketable securities [157]. - The company repaid $6.3 million under the Loan Agreement with Oxford Finance in October 2025, fully satisfying the outstanding amount [146].
Kezar Life Sciences(KZR) - 2025 Q3 - Quarterly Results
2025-11-12 21:07
Financial Position - As of September 30, 2025, Kezar Life Sciences, Inc. reported a preliminary cash, cash equivalents, and marketable securities position of $90.2 million[8]. Regulatory Updates - The company announced a regulatory update on its zetomipzomib program in autoimmune hepatitis[8]. - The press release regarding these updates was issued on October 16, 2025[8]. Strategic Alternatives - Kezar Life Sciences, Inc. is exploring strategic alternatives as part of its future growth strategy[8]. Rights Agreement - The Rights Agreement was amended to extend the Final Expiration Date to the day following the certification of the voting results of the Company's 2026 annual meeting of stockholders[11]. - If stockholders approve the Rights Agreement at the 2026 meeting, the expiration will extend to the day following the certification of the 2027 meeting results[11]. - The Rights Agreement remains unmodified and in full force and effect[11]. Company Classification and Listing - The company is classified as an emerging growth company under the Securities Act of 1933[6]. - The company is listed on The Nasdaq Stock Market LLC under the symbol KZR[5]. Report Signing - The report was signed by Marc L. Belsky, Chief Financial Officer and Secretary, on October 16, 2025[18].
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Businesswire· 2025-11-07 12:01
Core Insights - Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases [1] - The company announced two presentations from the completed Phase 2a PORTOLA clinical trial for autoimmune hepatitis at The Liver Meeting 2025 [1] - The event is organized by the American Association for the Study of Liver Disease and will take place from November 7-11 in Washington, DC [1]
Morning Market Movers: ARTV, AREB, AKAN, KXR See Big Swings
RTTNews· 2025-10-17 11:39
Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Artiva Biotherapeutics, Inc. (ARTV) has increased by 124% to $6.22 [3] - Akanda Corp. (AKAN) is up 39% at $3.10 [3] - Kezar Life Sciences, Inc. (KZR) has risen 38% to $5.80 [3] - Carbon Revolution Public Limited Company (CREV) is also up 38% at $5.15 [3] - Safe & Green Holdings Corp. (SGBX) has increased by 28% to $3.96 [3] - Achieve Life Sciences, Inc. (ACHV) is up 23% at $3.80 [3] - Revolution Medicines, Inc. (RVMD) has risen 8% to $53.90 [3] - Erayak Power Solution Group Inc. (RAYA) is up 8% at $5.76 [3] - ProQR Therapeutics N.V. (PRQR) has increased by 7% to $3.00 [3] - Bio Green Med Solution, Inc. (BGMS) is up 6% at $4.04 [3] Premarket Losers - American Rebel Holdings, Inc. (AREB) has decreased by 41% to $2.09 [4] - Sadot Group Inc. (SDOT) is down 25% at $5.35 [4] - AVITA Medical, Inc. (RCEL) has fallen 24% to $4.04 [4] - Soluna Holdings, Inc. (SLNH) is down 23% at $3.22 [4] - American Battery Technology Company (ABAT) has decreased by 17% to $4.70 [4] - CID HoldCo, Inc. (DAIC) is down 17% at $2.16 [4] - Pinnacle Food Group Limited (PFAI) has fallen 12% to $3.12 [4] - OnKure Therapeutics, Inc. (OKUR) is down 12% at $2.52 [4] - Whitehawk Therapeutics, Inc. (WHWK) has decreased by 12% to $2.29 [4] - Aqua Metals, Inc. (AQMS) is down 7% at $14.50 [4]
